Overview / Abstract: |
Target Audience This activity has been designed to address the educational needs of medical oncologists. It may also be of benefit to other healthcare professionals (HCPs) who manage patients with non-small cell lung cancer (NSCLC). Program Overview The first-line treatment of advanced NSCLC without actionable mutations has undergone a dramatic change over the last 5 years, with the standard of care changing from chemotherapy to immune checkpoint inhibitor (ICI) monotherapy for select patients, to a variety of ICI-based combination regimens in addition to monotherapy. In addition, several more ICI-based regimens are currently under US Food and Drug Administration (FDA) review and are expected to be added to the armamentarium in the near future. Although these multiple first-line regimens provide oncology clinicians and their patients with options to select from, this also creates a major challenge: Remaining up to date on the latest clinical trial data for existing and emerging ICI-based regimens, as well as applying these changes to improve treatment selection. Learning Objectives Upon completion of this activity, participants should be better able to: Evaluate the latest clinical trial data on immunotherapy-based combination regimens for the first-line treatment of NSCLC. Review of guideline recommendations for the use of ICI-based regimens |
Expiration |
Jan 31, 2022 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
0.5 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Matthew D. Hellmann, MD Karen Reckamp, MD, MS |
Sponsors / Supporters / Grant Providers |
Bristol-Myers Squibb Company and Merck & Co, Inc. |
Keywords / Search Terms |
Relias LLC Relias LLC., Free CME., NSCLC ,PD-L1 Expression Free CE CME |